Pyloric Botox Injections for Gastroparesis Treatment

Pyloric botox is an injection of botulinum toxin directly into the pylorus, the muscular valve between the stomach and small intestine, most commonly used as a treatment for gastroparesis when standard medications fail. Despite widespread use and encouraging early reports, the procedure has never been approved by regulatory agencies for this purpose, and two randomized controlled trials found it was no better than a placebo for most patients. The story of pyloric botox is one of a treatment that looked promising in open-label studies, then stumbled under rigorous testing, yet continues to be used in carefully selected patients and specific surgical settings where some evidence still supports it.

How the Injection Works

The pylorus is a ring of smooth muscle that controls how quickly food leaves the stomach. In gastroparesis, the stomach empties too slowly, causing nausea, vomiting, bloating, and pain. One proposed contributor is pyloric dysfunction: the valve contracts too forcefully or stays closed too long, creating a bottleneck. Botulinum toxin, injected endoscopically into the pyloric muscle during an upper endoscopy, blocks the release of acetylcholine from the nerve endings that tell the muscle to contract. At lower concentrations, it selectively inhibits nerve-driven contractions without affecting the muscle’s ability to respond directly to acetylcholine, which suggests the toxin is primarily working on the nerve-muscle communication rather than paralyzing the muscle outright.¹ The idea is straightforward: relax the gatekeeper, and food can pass through more easily.

Early Studies That Built Enthusiasm

The first wave of research on pyloric botox consisted of small, unblinded studies, and the results were genuinely exciting. In one of the earliest reports on patients with diabetic gastroparesis, botulinum toxin injection improved both symptoms and gastric emptying by about 52% at two and six weeks after treatment.² Another small study of seven patients with diabetic gastroparesis found that average symptom scores dropped from 27 to about 12, physical functioning improved, and six of seven patients gained weight, a meaningful outcome for people who often lose weight because eating makes them miserable.³ A separate study in idiopathic gastroparesis showed that symptom improvement tended to track with faster emptying of solid food from the stomach, hinting that the mechanism made sense.⁴

These results were hard to ignore. Gastroenterologists began offering pyloric botox off-label with increasing frequency, particularly for patients who had failed standard drug therapy. The problem, though, was that none of these studies had a control group receiving a sham injection. In gastroparesis research, placebo response rates are notoriously high: patients who believe they are receiving treatment often improve substantially regardless of what is injected.

What the Controlled Trials Actually Showed

The enthusiasm hit a wall when two randomized, placebo-controlled trials tested pyloric botox against sham injections. The most widely cited is a crossover study in which patients with predominantly idiopathic gastroparesis received either botulinum toxin or saline into the pylorus, then switched. The results were sobering: there was no significant difference between botox and placebo in gastric emptying speed, meal-related symptoms, or overall symptom severity scores.⁵ Both groups improved, but botox did not improve more than the placebo. A second randomized trial reached similar conclusions. The cumulative weight of this evidence shifted expert opinion substantially.

Researchers have debated why the open-label studies looked so good and the controlled trials did not. Part of it is almost certainly the placebo effect. Another possibility is patient selection: the early studies often focused on diabetic gastroparesis, while the randomized trials enrolled more patients with idiopathic gastroparesis. Some investigators suspect the pyloric dysfunction that botox targets may be present in only a subset of gastroparesis patients, and lumping everyone together dilutes any real benefit. That suspicion has driven efforts to better identify who might actually respond.

What Guidelines Recommend

Based on the randomized trial data, professional societies have taken a clear position. The European Society of Gastrointestinal Endoscopy issued a strong recommendation against botulinum toxin injection in unselected gastroparesis patients, rating the quality of evidence as high. At the same time, the ESGE noted that pylorus-directed therapy in general should be considered only in patients who have both symptoms consistent with gastroparesis and objective proof of delayed gastric emptying on a validated test, and only after medical therapy has failed.⁶ The emphasis on “unselected” is important: the guidelines do not say pyloric botox never works, but that giving it to every gastroparesis patient is not supported by the evidence.

In the United States, pyloric botox remains an off-label use of botulinum toxin. It has never received FDA approval for gastroparesis, and reviews of the evidence have suggested that further use outside of research trials is difficult to justify for the general gastroparesis population.⁷ That said, clinical practice is messier than guidelines. Many gastroenterologists still offer pyloric botox as a therapeutic trial in patients who have exhausted other options, particularly when newer tools suggest the patient’s pylorus is genuinely part of the problem.

Predicting Who Will Respond

If pyloric botox works only in patients whose pylorus is dysfunctional, the logical next step is to measure pyloric function before deciding to inject. A technology called EndoFLIP (endolumenal functional lumen imaging probe) does exactly this. EndoFLIP is essentially a balloon that measures how easily the pylorus stretches, expressed as its distensibility. A stiff, low-distensibility pylorus is more likely to be causing the obstruction that botox could relieve.

Research supports this approach. A study found that pyloric distensibility measurements taken before injection predicted which patients experienced symptom improvement and better quality of life three months later.⁸ EndoFLIP is also being explored in pediatric populations with neuromuscular conditions and significant foregut symptoms.⁹ The appeal of this measurement is that it moves beyond the blunt question of “does the stomach empty slowly?” and toward a more precise question: “is the pylorus the reason?” Patients whose pylorus is genuinely tight and resistant to distension are more likely to benefit. Patients whose gastroparesis stems from impaired stomach contractions or nerve damage elsewhere may not benefit at all, regardless of what is injected into the pylorus.

This concept of selecting patients based on measurable pyloric dysfunction, rather than treating everyone with a delayed emptying scan, is where most of the current research momentum lies. It also helps explain why randomized trials of unselected patients were negative: if only a fraction of participants had the specific problem botox addresses, any real effect would be drowned out statistically by the non-responders.

How Long the Effect Lasts

Even in patients who do respond, pyloric botox is not permanent. The toxin’s nerve-blocking effect wears off as nerve terminals regenerate, and symptoms typically return. In a study of patients with post-vagotomy gastroparesis, symptoms improved at one and three months after injection but had returned to baseline by six months.¹⁰ A pediatric study that tracked outcomes over time found a median recurrence interval of about 3.7 months after successful treatment.¹¹

This transient nature is both a limitation and, in a sense, a feature. It means a patient who does not respond simply waits a few months for the effect to clear, with no permanent damage done. But for patients who do respond, it means repeated endoscopic procedures and injections, sometimes indefinitely. That cycle of temporary relief followed by symptom return is a significant practical downside and one reason gastroenterologists have been searching for more durable alternatives.

Use After Esophageal Surgery

A distinct and active area of research involves pyloric botox given during or after esophagectomy, the surgical removal of part of the esophagus, most commonly performed for esophageal cancer. A common complication of this surgery is delayed gastric emptying, because the vagus nerve that controls stomach motility is often cut during the operation. To prevent this, surgeons sometimes inject botulinum toxin into the pylorus at the time of surgery, or perform a pyloroplasty (a surgical widening of the pyloric opening).

The evidence here is mixed but generally more favorable than in gastroparesis. A systematic review and meta-analysis pooling over 500 patients from five studies found no statistically significant difference in delayed emptying rates between botox injection and no injection, and no difference between botox and pyloroplasty.¹² However, a large single-center comparison found that patients who received intraoperative botox had shorter hospital stays than those who underwent pyloric surgery, even though the surgery group had slightly lower rates of delayed emptying.¹³ Botox patients also lost less weight postoperatively. In the same study, when pyloroplasty and pyloromyotomy were analyzed separately, pyloroplasty had the lowest delayed emptying rate but the highest bile reflux.

For patients who develop delayed emptying after esophagectomy despite initial preventive measures, endoscopic pyloric botox combined with balloon dilation has been used as a rescue therapy. In one ten-year institutional experience, 85% of patients who received this combined approach reported significant symptomatic improvement.¹⁴ The post-surgical setting differs from gastroparesis in an important way: the cause of slow emptying is often more clearly tied to disrupted nerve supply and pyloric spasm, making the rationale for botox more straightforward.

Pyloric Botox in Children

Pediatric use of pyloric botox is growing, though the evidence base is even thinner than in adults. A meta-analysis that pooled data from multiple studies found that about two-thirds of children with gastroparesis responded to intrapyloric botulinum toxin injection, and roughly the same proportion responded regardless of whether they technically met the criteria for gastroparesis.¹⁵ That last point is interesting: some children with functional upper gastrointestinal symptoms but normal emptying times on testing also improved, suggesting the injection may help with pyloric-related symptoms beyond what a standard emptying scan captures.

A recent review emphasized that pyloric botox in children is minimally invasive, reversible, and generally well tolerated, with mostly mild and self-limited side effects. However, the same review noted that pediatric use is almost entirely off-label, and the evidence comes from small case series rather than randomized trials.¹⁶ The reversibility of the treatment is particularly valued in children, where permanent surgical interventions carry higher stakes and where the underlying condition may change as the child grows.

G-POEM as a More Durable Alternative

Gastric peroral endoscopic myotomy, or G-POEM, is a newer endoscopic procedure in which the pyloric muscle is cut from the inside using a flexible scope passed through the mouth. Unlike botox, which temporarily relaxes the pylorus, G-POEM permanently divides the muscle fibers. It has emerged as the leading contender for a durable, pylorus-directed intervention in refractory gastroparesis.

The first head-to-head randomized trial comparing G-POEM to pyloric botox found that G-POEM achieved clinical success in 65% of patients at three months compared to 40% for botox, and 60% versus 40% at one year. Neither difference reached statistical significance in this relatively small study, but the trend consistently favored G-POEM. Gastric emptying improved in 72% of G-POEM patients versus 50% of botox patients. Only three minor adverse events occurred, all in the G-POEM group.¹⁷ Institutional experience and systematic reviews have generally echoed this pattern, finding G-POEM leads to greater improvement in both emptying times and symptom scores.¹⁸

Cost enters the conversation here. A cost-effectiveness analysis found that at three months, botox was the cost-effective strategy because G-POEM costs substantially more upfront and the short-term benefit gap was small. But at twelve months, the calculus reversed: because botox requires repeated injections while G-POEM is a one-time procedure, G-POEM became the cost-effective option over a longer horizon.¹⁹ This makes pyloric botox potentially useful as a test run: if a patient responds well to botox, it suggests their pylorus is the problem, and G-POEM may offer a longer-lasting fix. If they don’t respond, G-POEM is less likely to work either, and a more expensive, irreversible procedure has been avoided.

Safety and Rare Complications

Pyloric botox is generally considered safe. Most studies report no complications, and the procedure itself takes only a few minutes during a routine upper endoscopy. Side effects, when they occur, tend to be mild. But rare, serious events have been documented. The most striking is a case report of systemic botulism toxicity in a patient with Emery-Dreifuss muscular dystrophy (EDMD) who received a standard pyloric botox injection. The patient developed widespread muscle weakness consistent with systemic botulism. The investigators hypothesized that her underlying neuromuscular disorder left her muscles with so little reserve capacity to respond to nerve signals that even a localized injection pushed her over the edge.²⁰ This was the first documented case of systemic botulism from a pyloric injection, and it underscores the need for extra caution in patients with neuromuscular diseases.

Another practical safety consideration involves what happens if a patient later needs surgery. Botulinum toxin injections cause fibrosis (scar tissue) in the treated area. In the context of esophageal achalasia, where botox is injected into the lower esophageal sphincter rather than the pylorus, studies have found that prior botox treatment makes the tissue planes harder to separate during subsequent surgical myotomy. However, the success rates of the later surgery remained comparable between patients with and without prior botox.²¹ Whether the same pattern holds for pyloric botox followed by G-POEM is not yet well established, but it is a factor gastroenterologists weigh when sequencing treatments.

The Role of Pyloric Botox in Practice Today

The trajectory of pyloric botox illustrates a pattern familiar in gastroenterology: a plausible mechanism, promising case series, then disappointing randomized trial results that complicate rather than clarify the picture. The treatment has not been abandoned, but its role has narrowed. Rather than a first-line or even second-line treatment for gastroparesis broadly, it functions more as a diagnostic and therapeutic trial in carefully selected patients, particularly those with measurable pyloric dysfunction or those being evaluated for G-POEM. In the post-surgical setting, especially after esophagectomy, the evidence is more supportive, and the clear anatomical reason for pyloric dysfunction makes the treatment rationale stronger. In children, the reversibility and low complication rate make it an appealing temporizing option when other treatments have failed, even in the absence of large controlled trials. The gap between the evidence and the practice is real, and the field knows it. The research priority now is not whether pyloric botox works in general, but how to identify the minority of patients in whom it does.